CR20220508A - Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica - Google Patents

Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica

Info

Publication number
CR20220508A
CR20220508A CR20220508A CR20220508A CR20220508A CR 20220508 A CR20220508 A CR 20220508A CR 20220508 A CR20220508 A CR 20220508A CR 20220508 A CR20220508 A CR 20220508A CR 20220508 A CR20220508 A CR 20220508A
Authority
CR
Costa Rica
Prior art keywords
preventing
infectious disease
rna viral
viral infectious
pharmaceutical composition
Prior art date
Application number
CR20220508A
Other languages
English (en)
Inventor
Chung Ju
Hyun Kyu Chung
Jei Man Ryu
Geum Sil Cho
Original Assignee
Shin Poong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Poong Pharmaceutical Co Ltd filed Critical Shin Poong Pharmaceutical Co Ltd
Publication of CR20220508A publication Critical patent/CR20220508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona al uso de pironaridina o una sal farmacéuticamente aceptable de la misma, 5 y/o artemisinina o un derivado de la misma para la prevención o tratamiento de infecciones por virus de ARN epidémicas. Más específicamente, la presente invención se relaciona a una composición farmacéutica para la prevención o tratamiento de infecciones por virus de ARN epidémicas¿específicamente, 10 enfermedad por coronavirus 2019 (COVID-19), que comprende una cantidad terapéuticamente efectiva de pironaridina o una sal farmacéuticamente aceptable de la misma, y/o artemisinina o un derivado de la misma, junto con un portador farmacéuticamente aceptable.
CR20220508A 2020-03-26 2021-03-25 Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica CR20220508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200037135 2020-03-26
PCT/KR2021/003742 WO2021194290A1 (ko) 2020-03-26 2021-03-25 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물

Publications (1)

Publication Number Publication Date
CR20220508A true CR20220508A (es) 2023-04-25

Family

ID=77892085

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220508A CR20220508A (es) 2020-03-26 2021-03-25 Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica

Country Status (20)

Country Link
US (1) US12485116B2 (es)
EP (1) EP4129290B1 (es)
JP (1) JP2023519277A (es)
KR (2) KR102828536B1 (es)
CN (1) CN115666572B (es)
AU (1) AU2021244009A1 (es)
BR (1) BR112022019198A2 (es)
CA (1) CA3172672A1 (es)
CL (1) CL2022002588A1 (es)
CO (1) CO2022014992A2 (es)
CR (1) CR20220508A (es)
EC (1) ECSP22081150A (es)
ES (1) ES3040436T3 (es)
IL (1) IL296721A (es)
MX (1) MX2022011885A (es)
PE (1) PE20230041A1 (es)
PH (1) PH12022552516A1 (es)
PL (1) PL4129290T3 (es)
UA (1) UA130231C2 (es)
WO (1) WO2021194290A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111803491A (zh) * 2020-07-24 2020-10-23 中国人民解放军军事科学院军事医学研究院 青蒿素类化合物在治疗冠状病毒感染方面的应用
WO2022076565A1 (en) * 2020-10-07 2022-04-14 Sorrento Therapeutics, Inc. Salicylanilide analogs for use in the treatment of coronavirus
US20250177419A1 (en) * 2022-03-08 2025-06-05 Webiotree Co., Ltd Pharmaceutical composition comprising niclosamide or pharmaceutically acceptable salt thereof and preparation method therefor
CN116966178B (zh) * 2022-04-29 2025-10-03 成都贝诺科成生物科技有限公司 一种氨基硝基噻唑衍生物在制备预防和治疗病毒感染及其引起的相关疾病的药物中的用途
WO2025153638A1 (en) * 2024-01-19 2025-07-24 Pamoja Therapeutics Bv Highly concentrated liquid aqueous pyronaridine formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
DE602004029651D1 (de) * 2003-02-12 2010-12-02 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
US20110206636A1 (en) * 2003-09-16 2011-08-25 Kemin Foods, LLC Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
KR100623322B1 (ko) * 2004-11-02 2006-09-19 신풍제약주식회사 경구투여용 항말라리아 배합 제제 및 그의 제조방법
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
CN101857613B (zh) * 2010-06-03 2012-04-18 中国科学院新疆理化技术研究所 一枝蒿酮酸糖酯类衍生物及其制备方法和用途
CN101898966B (zh) * 2010-07-15 2013-04-17 中国科学院新疆理化技术研究所 含哌嗪环的一枝蒿酮酸酯类衍生物及其制备方法
JP5750274B2 (ja) * 2011-02-15 2015-07-15 株式会社ブリヂストン ゴムクローラ
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
US20140011829A1 (en) * 2012-07-06 2014-01-09 Robert Lewis Steele Artemisinin-Based Combination Therapy For Treating Viral Mediated Disease
CN105168500B (zh) 2015-09-11 2018-08-17 青岛大学附属医院 一种用于治疗小儿口腔溃疡的药物组合物及其制备方法
US11696914B1 (en) * 2019-11-06 2023-07-11 Collaborations Pharmaceuticals, Inc. Use of pyronaridine, tilorone, and quinacrine against Marburg virus and other virus infections
WO2021186396A2 (en) 2020-03-18 2021-09-23 Oncotelic Inc. Tgf-beta inhibition, agents and composition therefor

Also Published As

Publication number Publication date
ES3040436T3 (en) 2025-10-30
CN115666572B (zh) 2025-03-28
PL4129290T3 (pl) 2025-10-13
KR20210120891A (ko) 2021-10-07
CN115666572A (zh) 2023-01-31
MX2022011885A (es) 2022-10-21
AU2021244009A1 (en) 2022-10-27
EP4129290C0 (en) 2025-07-09
KR20240108337A (ko) 2024-07-09
EP4129290B1 (en) 2025-07-09
ECSP22081150A (es) 2023-02-28
BR112022019198A2 (pt) 2022-11-16
US12485116B2 (en) 2025-12-02
KR102828536B1 (ko) 2025-07-02
WO2021194290A1 (ko) 2021-09-30
UA130231C2 (uk) 2025-12-24
US20230132036A1 (en) 2023-04-27
CO2022014992A2 (es) 2022-11-29
IL296721A (en) 2022-11-01
PH12022552516A1 (en) 2022-11-07
JP2023519277A (ja) 2023-05-10
EP4129290A4 (en) 2023-08-30
EP4129290A1 (en) 2023-02-08
CA3172672A1 (en) 2021-09-30
PE20230041A1 (es) 2023-01-10
KR102910416B1 (ko) 2026-01-14
CL2022002588A1 (es) 2023-05-26

Similar Documents

Publication Publication Date Title
PH12022552516A1 (en) Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease
EP4643882A3 (en) Capsid inhibitors for the prevention of hiv
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
TW200745111A (en) New compounds
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
EA200702242A1 (ru) Использование сульфонамидного соединения для улучшения фармакокинетики лекарственного средства
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
SE0102440D0 (sv) New compound
TW200606164A (en) New compounds
MX2025012741A (es) Composiciones farmaceuticas orales
TW200800984A (en) New compounds
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors